FDA panel backs approval of Lupus drug

The first new treatment for lupus in more than 50 years passed a key hurdle Tuesday with a 13-2 vote by government advisers favoring approval.

The verdict for the drug Benlysta by a Food and Drug Administration advisory panel represents a victory for Human Genome Sciences Inc., a small biotechnology company that after 18 years in business finally appears on the verge of bringing its first major product to doctors’ offices.

[Wall Street Journal]